Elicio Therapeutics, Inc. (ELTX) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, specifically focusing on its lead candidate ELI-002, a lymph node-targeted therapeutic cancer vaccine for mutant KRAS cancers. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11.2) million | $(11.8) million |
| Operating Expenses | $10.7 million | $10.2 million |
| Cash and Cash Equivalents | $18.4 million | $11.9 million |
| Net Cash Used in Operating Activities | $(10.1) million | $(12.1) million |
| Debt | $0 (Convertible note converted to equity) | $20.0 million (Outstanding at Dec 31, 2024) |
| Accumulated Deficit | $(205.3) million | $(154.0) million |
Material Changes vs. Prior Period
- Debt Elimination: In March 2025, the company converted a $20.0 million Senior Secured Convertible Note (plus accrued interest) into 3.5 million shares of common stock, resulting in zero outstanding debt as of March 31, 2025.
- Capital Raises: The company raised approximately $9.2 million in net proceeds from a registered direct offering (January Offering) and $0.8 million from an At-the-Market (ATM) offering during the quarter.
- Expense Trends: Research and Development (R&D) expenses increased slightly by 3% ($7.8M vs $7.6M) due to the full enrollment of the ELI-002 Phase 2 trial. General and Administrative (G&A) expenses rose 10% ($3.0M vs $2.7M) primarily due to professional fees associated with the January Offering.
- Other Income/Expense: Net other expense decreased significantly from $1.6 million to $0.5 million, driven by a reduction in the loss from the change in fair value of warrant liabilities.
Guidance, Outlook, and Risks
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management estimates current cash resources will fund operations only into the fourth quarter of 2025.
- Financing Needs: Additional financing is required to continue development. Plans include public/private equity offerings, debt financing, or strategic collaborations, with no assurance of success.
- Clinical Outlook: The Phase 2 study for ELI-002 is progressing toward a disease-free survival event-driven interim analysis expected in Q3 2025.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting related to insufficient resources for complex accounting transactions and inadequate period-end close controls. Remediation efforts are underway but not yet complete.
- Risk Factors: Risks include potential impacts from new U.S. tariffs (announced April 2025), reliance on third-party manufacturers, and the uncertainty of clinical trial results.
Investor Verification Checklist
- Verify the sufficiency of the $18.4 million cash balance against the projected burn rate to confirm the Q4 2025 runway estimate.
- Review the status of the material weaknesses in internal controls and the progress of the remediation plan.
- Monitor upcoming financing announcements given the "substantial doubt" disclosure and the need for capital before Q4 2025.
- Track the timeline for the ELI-002 Phase 2 interim analysis expected in Q3 2025.
- Assess the impact of recent U.S. tariff announcements on supply chain costs for clinical trial materials.